Dr. Christoph Huber

Christoph Huber was Ugur Sahin's mentor and scientific collaborator who co-founded Ganymed Pharmaceuticals in 2001 alongside Sahin and Tureci. At Ganymed, Huber contributed to the development of zolbetuximab, the monoclonal antibody that demonstrated significant survival benefit in gastric cancer and led to Astellas Pharma's $436+ million acquisition in 2016. Huber's scientific expertise in antibody development and translational medicine provided the technical foundation for BioNTech's early platform work, though he has maintained a lower public profile than Sahin and Tureci in the company's subsequent growth.

Christoph Huber is an Austrian hematologist-oncologist and co-founder of BioNTech. As head of hematology and oncology at the University of Mainz he mentored Ugur Sahin and Özlem Türeci, and he co-founded Ganymed Pharmaceuticals with them in 2001. Ganymed developed zolbetuximab, a CLDN18.2 antibody for gastric and gastroesophageal cancers, and was acquired by Astellas Pharma in 2016. Huber brought experience in clinical immunotherapy and translational research to BioNTech's founding in 2008, helping set up its early clinical work in Mainz. He has kept a lower public profile than Sahin and Türeci, but shared the 2021 German Future Prize with them and Katalin Karikó for the work behind the mRNA COVID-19 vaccine. (Exact birth year remains publicly undisclosed).